OrthoPediatrics (NASDAQ:KIDS) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of OrthoPediatrics (NASDAQ:KIDS) from a hold rating to a sell rating in a report released on Saturday.

KIDS has been the subject of a number of other reports. Stifel Nicolaus decreased their target price on OrthoPediatrics from $32.00 to $20.00 and set a “buy” rating for the company in a research note on Friday. Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Wednesday, October 8th. BTIG Research decreased their target price on OrthoPediatrics from $39.00 to $23.00 and set a “buy” rating for the company in a research note on Friday. Lake Street Capital cut their price target on OrthoPediatrics from $37.00 to $34.00 and set a “buy” rating on the stock in a report on Friday. Finally, Citigroup restated an “outperform” rating on shares of OrthoPediatrics in a report on Friday. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $26.29.

OrthoPediatrics Stock Up 7.4%

NASDAQ:KIDS opened at $17.51 on Friday. OrthoPediatrics has a 1 year low of $15.28 and a 1 year high of $32.00. The company has a current ratio of 6.66, a quick ratio of 3.43 and a debt-to-equity ratio of 0.27. The stock has a market cap of $438.98 million, a price-to-earnings ratio of -9.78 and a beta of 1.02. The stock has a 50-day moving average price of $19.43 and a two-hundred day moving average price of $20.94.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Monday, January 9th. The company reported ($0.15) earnings per share (EPS) for the quarter. OrthoPediatrics had a negative net margin of 18.92% and a negative return on equity of 6.36%. The business had revenue of $25.08 million during the quarter. As a group, equities analysts expect that OrthoPediatrics will post -0.93 earnings per share for the current year.

Insider Activity at OrthoPediatrics

In related news, CFO Fred Hite bought 5,076 shares of the company’s stock in a transaction that occurred on Thursday, August 21st. The shares were acquired at an average price of $19.41 per share, for a total transaction of $98,525.16. Following the completion of the acquisition, the chief financial officer owned 213,065 shares of the company’s stock, valued at approximately $4,135,591.65. The trade was a 2.44% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 31.80% of the stock is currently owned by company insiders.

Institutional Trading of OrthoPediatrics

Institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC raised its holdings in OrthoPediatrics by 4,618.2% during the first quarter. GAMMA Investing LLC now owns 10,616 shares of the company’s stock worth $261,000 after acquiring an additional 10,391 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in OrthoPediatrics by 112.3% during the first quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock worth $4,937,000 after acquiring an additional 106,041 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in OrthoPediatrics by 116.5% during the second quarter. Harbor Capital Advisors Inc. now owns 333,959 shares of the company’s stock worth $7,173,000 after acquiring an additional 179,733 shares in the last quarter. Invesco Ltd. raised its holdings in OrthoPediatrics by 12.1% during the first quarter. Invesco Ltd. now owns 18,349 shares of the company’s stock worth $452,000 after acquiring an additional 1,986 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in OrthoPediatrics by 175.0% during the first quarter. SG Americas Securities LLC now owns 20,039 shares of the company’s stock worth $494,000 after acquiring an additional 12,753 shares in the last quarter. Institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.